Discontinuation of anticoagulant therapy for a month in a patient with HeartMate III continuous-flow left ventricular assist device without thromboembolic events

The recommended anticoagulation regimen for continuous-flow left ventricular assist device (LVAD) systems is warfarin and aspirin with a targeted international normalized ratio (INR) of 2.0–3.0. Our patient is a 58-year-old male who underwent surgical HeartMate III continuous-flow LVAD implantation...

Full description

Saved in:
Bibliographic Details
Published inJournal Of The Saudi Heart Association Vol. 30; no. 3; pp. 268 - 270
Main Authors Elasfar, Abdelfatah, Jalali, Kafaf, Hussein, Mohamed, AlHarbi, Ibraheem, Amoudi, Osama
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.07.2018
Elsevier
Saudi Heart Association
Subjects
Anticoagulation
Case Report
Continuous flow LVADs
Heart Mate III
Continuous flow LVADs
Anticoagulation
Heart Mate III
Online AccessGet full text

Cover

More Information
Summary:The recommended anticoagulation regimen for continuous-flow left ventricular assist device (LVAD) systems is warfarin and aspirin with a targeted international normalized ratio (INR) of 2.0–3.0. Our patient is a 58-year-old male who underwent surgical HeartMate III continuous-flow LVAD implantation 3 months ago outside the country. The patient mistakenly stopped taking warfarin for 1 month prior to presenting to our center for a routine visit. Luckily, the patient was doing very well without any complication despite the fact that his INR was 1.0.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1016-7315
2212-5043
DOI:10.1016/j.jsha.2017.12.002